Compare AbbVie Inc (ABBV) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Hyatt Hotels Corporation — how do they compare? AbbVie Inc trades at $253.86 (market cap $449.91B), while Hyatt Hotels Corporation trades at $188.99 (market cap $18.19B). The key difference: AbbVie Inc is far larger — about 24.7× Hyatt Hotels Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | H | |
|---|---|---|
Market Cap | $449.91B | $18.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $202.09 |
52-Week Low | $184.85 | $135.01 |
Enterprise Value | $513.38B | $22.03B |
Dividend Yield | 2.72% | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Hyatt Hotels (H) trades at $193.16, up 0.98% with a neutral technical signal. The stock shows mixed fundamentals with negative net income margins (-0.48%) and ROE (-1.02%) despite revenue growth to $7.1B in 2025. Recent earnings beat expectations in Q4 2025 and Q1 2026, while analyst consensus targets $197.30. The company continues expansion with new hotel announcements and maintains strong institutional support.
Investment outlook is cautiously optimistic given analyst buy ratings (37.5%) and expansion initiatives, but risks include declining cash flow trends and elevated debt levels. The stock faces pressure from negative profitability metrics despite revenue stability, requiring careful monitoring of upcoming Q2 2026 earnings against the $0.89 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
